Sophion user publications: Q4 2025’s seminal studies in ion channels
As we welcome 2026, we present the final quarterly review of Sophion users’ publications from Q4, 2025. There is an impressive culmination of research covering a multitude of ion channels, diseases, and innovative developments for the entire ion channel community.
While broad in scientific scope, Q4 carried a distinct emphasis on nature’s own molecular arsenal, with remarkable work exploring venoms, antivenoms, peptides, and natural products. These studies continue to demonstrate how Sophion’s automated patch clamp platforms empower researchers to unlock complex channel biology, innovate therapeutic strategies, and advance translational discoveries at pace.
- DTU collaboration yields innovative antivenom nanobodies
In our 2nd Nature paper for 2025, novel antivenom nanobodies were developed via Sophion’s ongoing collaboration with Profs. Andreas Laustsen & Tim Jenkins’ labs at DTU. - Novel peptide modulator of ASIC3 characterized
Dr. Chun Chien et al. at Latigo Biotherapeutics, Inc. used Sophion’s QPatch to characterize a new peptide, WRPRFa, revealing its ability to slow ASIC3 desensitization, enhance proton sensitivity, and uncover tachyphylaxis. - Tarantula toxin papers add to sodium channel pharmacology
Not one but two tarantula toxin papers targeting sodium channels (incl. the most selective Nav1.6 blocker to date) from the prolific publishing machine that is the University of Queensland in the labs of Dr. Fernanda Cardosa and Prof. Richard Lewis – Cardoso et al. and Nashikwala et al. - Pain therapeutics from marine organismsÂ
A Nav1.7 screen of natural extracts from marine algae, sponges, and corals towards novel pain therapeutics – Amatulla Nashikwala and Bhuwan Chettri et al.
Congratulations to all the authors featured in this 4th quarter review. Your research highlights the exciting advances and innovative work happening in the field. Which recent ion channel studies have caught your attention?